How many investments has Versant Ventures made?

Versant Ventures has 27 tracked investments.

What stage does Versant Ventures invest at?

Versant Ventures invests at the Seed, Series A, Series B, Series C, Late Stage stages.

What is Versant Ventures's typical check size?

Versant Ventures typically writes checks of $250K – $5M.

What sectors does Versant Ventures focus on?

Versant Ventures focuses on Biotech, Healthtech.

Where is Versant Ventures located?

Versant Ventures is headquartered in San Francisco, US.

Does Versant Ventures lead rounds?

Versant Ventures typically participates in rounds rather than leading them.

Who does Versant Ventures co-invest with?

Versant Ventures most often shares deals with RA Capital, Scion Life Sciences, Foresite Capital, among 33 tracked co-investors.

Versant Ventures

Venture capitaloperating company · company profile

San Francisco · Seed–Late Stage · 48 people tracked

Also known as Versant Capital Management, Inc. · VERSANT VENTURE MANAGEMENT, LLC

★ Follow + Add to CRM ⤳ Find an introduction

✨ Fox Verdict

Investment thesis

Versant Ventures focuses on building novel biotechnology companies, pairing academic founders with its in-house Discovery Engines—teams of multidisciplinary scientists operating state-of-the-art laboratory facilities. This model emphasizes translating scientific discoveries from academia into company creation within the biotech sector.

Invests inBiotech Healthtech Canada Europe North America San Francisco Switzerland United States

Source: firm website, verified Aug 25, 2026.

Stage

Seed–Late Stage

Check

$250K – $5M

San Francisco, CA, US

Leads rounds

Follows

Instruments

Equity

Founded

1999

Last 12 months

3 investments

AUM

$5.5B

VC funds

Tracked investments

Team · 48 people

from the firm's website & curated & public directories

Brad Bolzon· Chairman, Managing Director· Canada

Brad Bolzon merges 13 years of senior R&D and business development at Eli Lilly and Roche with architecting cross-border company creation—co-founding Inception Sciences, chairing CRISPR Therapeutics, and building multi-hub presence.

b•••@versantventures.comreveal

Alex Mayweg· Managing Director· Basel, Switzerlandin 𝕏

Managing Director at Versant and head of Ridgeline Therapeutics, Versant's Basel-based Discovery Engine, with deep experience in drug discovery and medicinal chemistry. He previously served as global head of chemistry at Roche over a 14-year career and holds a Ph.D. in organic chemistry from Oxford, with post-doctoral training at Stanford and an undergraduate degree from Imperial College London.

a•••@versantventures.comreveal

Carlo Rizzuto· Managing Director· New York, New Yorkin 𝕏

Carlo Rizzuto, a PhD virologist-turned-VC who pioneered and championed epitranscriptomics and backed Gotham Therapeutics early, is a hands-on builder who often serves as acting CEO/CBO to create first-wave biology companies.

c•••@versantventures.comreveal

Clare Ozawa· Managing Director· San Diego, Californiain

Clare Ozawa combines a Stanford Ph.D. with experience as COO/CBO at Inception Sciences, leads San Diego–Bay Area investments and sits on boards of Capsida, Lycia, Gate Bioscience and 858 Therapeutics.

c•••@versantventures.comreveal

Jerel Davis· Managing Director· Vancouver, BCin 𝕏

Jerel Davis is a PhD-trained life scientist and Vancouver-based investor who builds biotechs from scratch via pharma partnerships—co-founding BlueRock with Bayer ($225M) and designing ventures with acquirers in mind.

j•••@versantventures.comreveal

Markus Enzelberger· Partner· Munich, Germanyin

Markus is a Versant partner in Basel who helps launch new companies from the firm's Ridgeline Discovery Engine. A drug discovery and protein engineering expert, he previously served as CSO and management board member of MorphoSys, which he joined in 2002, and holds a Ph.D. from the Technical University of Stuttgart.

m•••@versantventures.comreveal

Nigel Sheail· Partner· Basel, Switzerlandin

Nigel Sheail is a Versant partner based in Basel with over two decades of pharmaceutical leadership experience. He previously served as Global Head of M&A and Business Development & Licensing at Novartis, and held business development and M&A leadership roles at Bayer Healthcare and Roche.

n•••@versantventures.comreveal

Tom Woiwode· Managing Director· San Francisco, Californiain

Tom Woiwode is a PhD medicinal chemist with operating experience as CBO/COO who led IPOs/M&A exits including CRISPR Therapeutics and co-founds companies early with academics like Jim Wilson (iECURE).

t•••@versantventures.comreveal

Ross Jaffe· Managing Director· Los Angeles, California, United Statesin

Barbara Lubash· Managing Director· Californiain

Barbara Lubash is Principal at Atlantic Pacific Advisors and has served as a board member and advisor for over 15 years across more than 10 corporate and nonprofit boards. She co-founded Versant Ventures, a firm focused on business-to-business tech-enabled health services and health technology companies, and previously held senior governance roles at California HealthCare Foundation, including Board Chair, where she oversaw the development of one of the first healthcare foundation Program Related Investment funds in the United States. Her experience spans health care operations, business innovation scaling, and strategic oversight functions including CEO succession, investment strategy, and audit and compliance committees.

Beckie Robertson· Managing Director· Palo Alto, California, United Statesin

Beckie Robertson is a Principal at Longridge Business Advisors. She has more than 30 years of experience in venture capital and operations, having worked as an engineer, entrepreneur, corporate executive, investor, board member, and business advisor. Her work has included advising management on business and technology strategy, financings, mergers and acquisitions, and organizational design.

Brian Atwood· Managing Director· Californiain

Ariel Kantor· Principal

A scientist and company builder who joined Versant after serving as Chief Business Officer at ReCode Therapeutics and as an Entrepreneur-in-Residence at Oxford Science Enterprises, with prior experience as an investment banker at Evercore Partners. He holds a B.S. from Duke and a Ph.D. in Clinical Neuroscience from Oxford as a Rhodes Scholar, and has co-founded companies in genetic medicines and RNA biology.

Joel Drewry· Principal· Toronto, Ontarioin 𝕏

Principal in Versant's Toronto office who joined in 2014 and has been involved in the creation and launch of several companies in the US and Canada, with a focus on early company formation. Holds a Ph.D. in organic chemistry from the University of Toronto (2012).

j•••@versantventures.comreveal

Mehmet Badur· Principal· San Diegoin

Mehmet Badur joined Versant in March 2022 as a Senior Associate and was promoted to Principal later that year, focusing on investments and company creation opportunities primarily on the West Coast. He previously worked at Rheos Medicines in business development and as a discovery scientist, and holds a PhD in Bioengineering from UC San Diego.

m•••@versantventures.comreveal

Michael Wong· Principal· Toronto, Canada

Principal at Versant focused on building and investing in new companies and driving pharma partnerships. Previously at Flagship Pioneering on the venture creation team, where he co-founded four biotech companies, and earlier co-founded and led ARCHITECHealth and Industry Link.

Nikita Sharma· Principal· Basel, Switzerlandin

Nikita Sharma joined Versant in February 2024 as a Principal based in Basel, supporting portfolio companies and new opportunities in Europe and North America. She previously served as M&A Director at Novartis, leading acquisitions of Chinook Therapeutics, Calypso Biotech and SanReno Therapeutics, and earlier held roles at Sandoz and Axalta. She holds an MBA from Symbiosis International University.

Kerrie Cohen· Principal· Americasin

Leads global communications and marketing for Warburg Pincus, covering the Americas region.

k•••@warburgpincus.comreveal

Alicia Levey· Venture Partner· San Francisco

Venture Partner in Versant's San Francisco office focused on investing and new company creation, with a background as a company creator, operator and dealmaker. She previously was President and COO of Pionyr Immunotherapeutics, held business development roles at Versant portfolio companies including Tempest Therapeutics and Inception Sciences, worked at Boston Consulting Group, and earned a Ph.D. in Cancer Biology from Stanford.

Kevin Grove· Venture Partner· Seattlein

Venture Partner focused on cardiometabolic disease, obesity and diabetes, with drug development and commercialization expertise. Joined Versant in July 2024 after nearly a decade at Novo Nordisk (where he founded its Seattle Obesity Research unit) and 20 years at Oregon Health Science University.

Monal Mehta· Venture Partner· New York Cityin

Monal Mehta is a Venture Partner in Versant's NYC office focused on early-stage healthcare companies. She was previously a Managing Director at Avidity Partners' Private Fund and served on several biotech boards, with prior roles in business development at Pfizer and consulting at Navigant. She holds a Ph.D. in Cancer Biology.

Peter Emtage· Venture Partner· San Francisco Bay Areain

Peter Emtage joined Versant Ventures as an Entrepreneur-in-Residence in October 2020 and became a Venture Partner in April 2021. He previously led cell therapy research at Kite Pharma (a Gilead company) and held senior scientific roles at Cell Design Labs and MedImmune, with over 20 years of drug development experience in oncology, autoimmunity, infectious diseases and inflammation.

Rami Hannoush· Venture Partner· San Diego and San Francisco Bay Areain

Venture partner focused on company creation, bringing both investment and drug discovery expertise. Previously a general partner at Mubadala Capital building its U.S. healthcare platform, co-founder and CEO of EpiBiologics, and a 16+ year Genentech R&D leader in oncology and immunology. Holds a Ph.D. in Chemistry from McGill with postdoctoral training at Harvard.

Richard Glynne· Venture Partner

Venture partner at Versant and president and CSO of Versant's Inception Sciences Discovery Engine, with expertise in developing and translating novel therapies. He joined Inception as CSO in 2018 after leading search and evaluation at Novartis and holding research leadership roles at the Genomics Institute of the Novartis Research Foundation, Eos Biotechnology, and Phenomix Corporation; he trained in immunology and genetics at ICRF London and Stanford (HHMI).

Tom Hudson· Venture Partner· Toronto

Venture partner supporting Versant's Frontier discovery engine in Toronto and contributing to new investments. He was previously SVP and chief scientific officer at AbbVie and the inaugural President and Scientific Director of the Ontario Institute for Cancer Research, and holds an M.D. from the University of Montreal.

Zach Sweeney· Venture Partner· San Francisco Bay Areain

Venture Partner at Versant with extensive experience leading drug discovery across small molecule, biotherapeutic, and technology platforms. Previously co-founded and served as CEO of Interline Therapeutics, was CSO of Denali Therapeutics, and held drug discovery leadership roles at Genentech, Roche, Novartis, and Revolution Medicines. He works with entrepreneurs to build new companies from early-stage science.

Omar El-Khalaf· Venture Partnerin

A Syrian-British entrepreneur and humanitarian who co-founded Empowerful, a charity initiative to empower students, in 2017.

Jeremy Caldwell· Venture Partner· San Diego, California𝕏

Markus Warmuth· Venture Partner· Cambridge, Massachusettsin 𝕏

Markus Warmuth serves as Chief Executive Officer at Monte Rosa Therapeutics and is a board member at Ventus Therapeutics. He is a physician scientist with experience in drug discovery, translational research, and clinical development across the pharmaceuticals industry.

Andrew Jefferson· Operating Partner

Operating Partner at Versant and COO of the firm's Ridgeline Discovery Engine, who joined in 2018 from Roche where he was VP of Business Development at Roche Molecular Solutions and previously Basel Site Head for Roche Partnering. He began his career in pharmaceutical manufacturing and worked in pharma business at Ciba-Geigy and Novartis in the UK, holding a BSc in Chemistry and an MBA.

Cathy Dring· Legal Counsel

Christine Mathews· Advisor

Ed Olhava· Scientist-in-Residence· San Francisco

Ed Olhava joined Versant in 2026 as a Scientist in Residence with over 20 years of experience leading small molecule drug discovery programs. He previously served as SVP of Preclinical Development at IFM Therapeutics, advised Third Rock Ventures, was the first medicinal chemist at Epizyme, and co-invented NINLARO at Millennium Pharmaceuticals.

Giorgio Ottaviani· Operating Partnerin

Operating Partner at Versant and SVP of Preclinical Development at the firm's Ridgeline Discovery Engine, with drug development expertise. He joined Ridgeline in 2018 from Roche, where he led DMPK-PD project leaders and headed non-clinical safety in Shanghai, and previously worked at Novartis and Merck-Serono. He holds a Ph.D. in Pharmaceutical Chemistry from the University of Geneva and is a certified toxicologist (DABT).

Kenan Sagouspe· Portfolio Analyst

Kim Macniak· Controller· San Francisco Bay Areain

Lara Hoth· VP, Management Company Finance and Accounting

Lara Hoth is Versant's VP of management company finance and accounting, working with the CFO on the firm's financial and administrative operations across the U.S., Canada, and Switzerland. Before joining Versant in 2016 she spent six years at Novartis, held controller roles at two other companies, and began her career at PricewaterhouseCoopers; she holds a BA from UC Berkeley.

Laura Quock· CBO-in-Residence· San Francisco, Californiain

Laura joined Versant in June 2024 as a CBO-in-Residence, focused on strengthening business development across Versant's portfolio companies. She previously served as Senior Director of Corporate Development at Gilead, led the MiroBio acquisition, and held roles at Genentech, AbbVie, and Abbott Laboratories. She holds an MBA and M.S. in Chemical Engineering from UC Berkeley and a B.S. in Chemical Engineering from Purdue University.

Max Eisenberg· Chief Operating Officer and General Counsel· San Franciscoin

Max Eisenberg is COO and General Counsel at Versant, overseeing legal aspects of investment transactions, management company operations, fundraising, HR, and regulatory compliance. He previously served as the first General Counsel and Chief Compliance Officer at Polaris Partners.

Rich Van Doren· Chief Financial Officer

Rich Van Doren is the CFO of Versant Ventures with about 20 years of financial experience, previously serving as CFO of Samsara Biocapital and holding CFO/COO roles at Pacific Grove Capital, Marcato Capital, and Cannell Capital. He holds a B.S. in Finance from the University of San Francisco and a Graduate Certificate in Tax from Golden Gate University.

r•••@versantventures.comreveal

Rick Dewey· Entrepreneur-in-Residence· Boston and New York Cityin

Rick Dewey joined Versant Ventures in 2024 as an Entrepreneur-in-Residence with over 15 years translating human genome insights into new medicines. He previously was Chief Scientific Officer of Foresite Labs and Head of Translational Genetics at Regeneron Genetics Center, and is a board-certified physician-scientist trained at Stanford.

Robin Praeger· Advisor· San Francisco, Californiain

Robin Praeger combined two decades as his firm's CFO (2000–2022) with investment leadership, bringing a CPA and Master of Taxation background that strengthens complex fund structuring and tax strategy.

Steve Edelson· VP, IR & Communications

Steve Edelson handles Versant's messaging, external and LP communications, and media relations. Before joining the firm, he spent 18 years at BioCentury Inc., rising from Staff Writer to Senior Editor and covering financial and emerging trends in the life science industry. He holds an M.S. in biotechnology and a B.A. in biochemistry from Northwestern University.

Vincent Ruland· Entrepreneur-in-Residence· Basel, Switzerlandin

Vincent Ruland joined Versant in August 2025 as an Entrepreneur-in-Residence in Basel, supporting existing portfolio companies and new opportunities in Europe and North America. He previously was SVP, Head of R&D Strategy, Portfolio and Operations at Bayer Pharmaceuticals, and is a physician-scientist trained in neuropathology with an M.D. from the University of Münster and an M.Phil. from the University of Cambridge.

Bryan Berg· CBO-in-Residence· Seattle, Washington, United Statesin 𝕏

Worked on early infrastructure and security at Stripe.

Didem Altop· Versant Venturesin 𝕏

General Partner at Treeo VC and founding managing director of Endeavor Turkey, where her work contributed to $2.7 billion in exits. She has launched six angel networks and advised the creation of seven VC funds.

d•••@treeo.vcreveal

Jeffrey M. Hurst· Entrepreneur in Residence· Dennis, Massachusetts, United Statesin

j•••@commonwealthvc.comreveal

Mohan Menon· Entrepreneur in Residencein

Managing Director at Richmond Global Ventures with three decades of company-building experience across four continents, Menon manages Smart City Technologies and is a Senior Advisor and Limited Partner at Meritage Funds. He previously held roles at Oracle, IBM, and J.D. Edwards.

m•••@rglobal.comreveal

Founder mafia

The Versant Ventures mafia →

11 people who came through Versant Ventures went on to found or lead other companies.

Peter EmtageVenture PartnerFounded Santa Ana +1 Erik T. EngelsonVenture PartnerFounded Medina Medical +1 Rami HannoushVenture PartnerFounded Epi Biologics Bryan BergCBO-in-ResidenceFounded Standardcap Beckie RobertsonManaging DirectorFounded Egis Paul SekhriOperating PartnerFounded Vtvtherapeutics Kevin HykesOperating PartnerFounded Augmedics Brian AtwoodManaging DirectorFounded Sindarin Marcelo BigalVenture PartnerFounded Ventus Therapeutics Markus WarmuthVenture PartnerFounded Monte Rosa Therapeutics Bobak Azamian, MD, PhDInvestment ProfessionalFounded Tarsus Pharmaceuticals

What they invest in

from 51 of 73 portfolio companies

Biotech ×44Healthtech ×30Medical Devices ×16AI & Machine Learning ×10Deep Tech ×8Digital Health ×3Hardware ×2Enterprise Software ×1

HQs:United States×39Switzerland×1United Kingdom×1Mexico×1

Investments · 73 tracked

founders shown can be your intro path

By year:2026 · 2 2025 · 4 2024 · 4 2023 · 4 2022 · 3 2021 · 2 2020 · 1 2019 · 2 2018 · 3 2017 · 2 2015 · 1 2014 · 130 dated

Monte Rosa Therapeuticsmonterosatx.com in 𝕏NASDAQ: GLUE✓ verified

Monte Rosa develops molecular glue degrader (MGD) therapeutics using MGD chemistry, artificial intelligence, structural biology, and proteomics to target previously undruggable or inadequately drugged disease targets.

AI & Machine LearningBiotechDeep TechHealthtechBoston, US

Markus Warmuth(M.D., Chief Executive Officer)inSharon Townson(Ph.D., Chief Scientific Officer)inJohn Castle(Ph.D., Chief Data and Information Officer)inFilip Janku(M.D., Ph.D., Chief Medical Officer)inPhil Nickson(Ph.D., J.D., Chief Business and Legal Officer)inMagnus Walter(DPhil, Chief Technology Officer)in

Co-investorsAisling Capital New Enterprise Associates (NEA)HBM Partners Amzak Health Avoro Capital Advisors GV (Google Ventures)+1 more

Century Therapeutics, Inc.centurytx.com inNASDAQ: IPSCMar 2021SEC filingmedium confidence

Century Therapeutics develops allogeneic, iPSC-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer.

BiotechHealthtechMedical DevicesPhiladelphia, US

Board seatCarlo Rizzuto· per SEC Form D · $160M raise · filed Mar 2021

Co-investorsCasdin Capital

Black Diamond TherapeuticsNASDAQ: BDTX

Co-investorsRA Capital

Passage Biopassagebio.com in 𝕏NASDAQ: PASG

Passage Bio is a biotechnology company developing treatments for central nervous system (CNS) diseases, with a focus on neurodegenerative conditions.

BiotechHealthtechPhiladelphia, US

Tadataka Yamada(Executive Officer, Director, Promoter)Stephen Squinto(Executive Officer, Director)

BoardPatrick Heron(Director)inCarl Gordon(Director)Thomas Street Address 1 Woiwode(Director)Saqib Islam(Director)

Co-investorsFrazier Life Sciences Access Biotechnology Frazier Healthcare Partners New Leaf Venture Partners OrbiMed Vivo Capital

Bright Peak Therapeuticsbrightpeaktx.com inJun 2024✓ verified

Bright Peak Therapeutics is a biotechnology company developing multi-functional PD-1 inhibitors for cancer immunotherapy, based on its EDC protein-engineering platform.

BiotechHealthtechSan Diego, US

Vijaya Pattabiraman(Co-founder & Chief Technology Officer)inJeffrey Bode(Scientific Co-founder)inFredrik Wiklund(Chief Executive Officer)Christine Siu(Director)Michael Rosenzweig(Director)Bertolt Kreft(Executive Officer)

Board seatTom WoiwodeAlex Mayweg· per SEC Form D

Co-investorsRA Capital Johnson & Johnson Innovation – JJDC Venrock Fidelity Investments Invus Qatar Investment Authority

Lycia Therapeuticslyciatx.com in 𝕏Jun 2026✓ verified

Lycia Therapeutics is a biotechnology company developing LYTAC (Lysosomal Targeting Chimera) therapeutics that bind disease-causing extracellular and cell-surface proteins and route them into the cell's lysosome for degradation.

BiotechHealthtechSouth San Francisco, US

Aetna Wun Trombley(President and CEO)inAmy Bachrodt(Chief Financial Officer)inChin Lee(Chief Medical Officer)inSteve Staben(Chief Scientific Officer)inSofia Touami(Chief Business Officer)inKaren Flick(General Counsel)in

Board seatClare Ozawa· per SEC Form D

Co-investorsREDMILE BAM Elevate Franklin Templeton HBM Healthcare Investments Invus Janus Henderson Investors +4 more

Allrockbioallrockbio.com in✓ verified

AllRock Bio is a drug development company advancing novel therapies for pulmonary hypertension, interstitial lung diseases, and other fibrotic conditions.

BiotechNatick, US

Catherine Pearce(CEO & Founder)DHSc(Founder)Justin R Thompson(Founder)in

Co-investorsWestlake BioPartners Westlake Village BioPartners

Capsidacapsida.com in 𝕏✓ verified

Capsida Biotherapeutics develops engineered gene therapies for rare and common neurological and ocular diseases using an AAV capsid platform that enables improved brain and retinal delivery compared to naturally occurring capsids.

BiotechDeep TechDigital HealthMedical Devices

Viviana GradinaruNick Goeden, Ph.D.(Co-founder)Nicholas Flytzanis(Co-founder)

Co-investorsWestlake Village BioPartners

Dualitas Therapeuticsdualitastx.com inJul 2025✓ verified

Dualitas Therapeutics develops bispecific antibody therapies that pair a proprietary proximity engager arm with an antibody against a therapeutic target, using its DualScreen discovery engine to identify synergistic target combinations.

BiotechDeep TechSouth San Francisco, US

Forbes Huang(Co-Founder, Chief Operating Officer & Chief Business Officer)inGreg Lazar(Co-Founder & Chief Scientific Officer)inRichard Murray(Executive Officer, Director)Karim Dabbagh(Chief Executive Officer, Board Member)in

BoardAlicia Levey(Director)Michael Ross(Director)

Co-investorsQiming Venture Partners SV Health Investors Alexandria Dementia Discovery Fund Qiming Healthcare Qiming Venture Partners USA

Fablefabletherapeutics.com✓ verified

Fable Therapeutics is a biotech company using protein engineering to develop biologics targeting the activin receptor type II (ActR2) pathway for obesity and related metabolic diseases.

BiotechHealthtechLongevity

Geoff MacKay(President & CEO)David Baker(Chief Scientific Officer)Rhonda Wideman(Chief Business Officer)Zack McNealy(Chief Financial Officer)

Co-investorsMPM BioImpact DCVC Bio Lilly Asia Ventures DCVC (Data Collective)

Gate Biogatebio.com✓ verified

Gate Bioscience develops small molecule therapeutics called Molecular Gates for disease treatment.

BiotechDeep TechMedical Devices

Jordi Mata-Fink(Chief Executive Officer, Co-Founder)inRaman Talwar(Chief Technology Officer, Co-Founder)inPat Sharp(Scientific Founder)in

Co-investorsForbion Andreessen Horowitz ARCH Venture Partners GV (Google Ventures)

Granite Biogranitebio.com inApr 2025 · $100M✓ verified

Granite Bio develops first-in-class therapeutic antibodies targeting inflammation, autoimmunity, and fibrosis for patients lacking effective treatment options.

BiotechMedical DevicesBasel, CH

Patrick Loustau(President and Chief Executive Officer)in

Co-investorsNovartis Venture Fund Sanofi Ventures Forbion

Iecureiecure.com✓ verified

iECURE is a clinical-stage biotechnology company developing in vivo genome editing therapies that insert a functional copy of a gene into a patient's genome to treat rare, life-threatening genetic diseases in children.

BiotechHealthtechMedical Devices

James M. Wilson(Scientific Founder)Joseph Truitt(CEO & Board Member)Paul Firuta(COO)Alex Monteith(Chief Business Officer)David Garrett(CFO)Gabriel M. Cohn(Chief Medical Officer)

Co-investorsOrbiMed LYFE Capital

Lighthorsetxlighthorsetx.com✓ verified

Light Horse Therapeutics is a drug discovery company applying scientific expertise and innovation to advance healthcare through collaborative development.

AI & Machine LearningBiotechMedical Devices

Co-investorsTaiho Ventures, LLC AbbVie Mubadala Capital

Nested Therapeuticsnestedtx.com in 𝕏✓ verified

Nested Therapeutics is a precision oncology company developing small-molecule cancer therapeutics by identifying overlooked driver mutations and novel binding pockets through a drug discovery platform combining genomics, computational biophysics, machine learning, and chemical biology.

AI & Machine LearningBiotechHealthtech

Arvin Dar(Co-founder & Board Observer)inKevan Shokat(Scientific Co-founder)Klaus Hoeflich(Co-founder & former Chief Scientific Officer)inDarrin Miles(Chief Executive Officer)inPhilip Komarnitsky(Chief Medical Officer)inTanja Weber(Chief Business Officer)

Co-investorsForesite Capital Sixty Degree Capital Cowen Healthcare Investments Goldman Sachs

Nexonexotx.com in✓ verified

Nexotx is a drug discovery company that identifies and develops medicines targeting previously undrugged biological pathways using chemical biology approaches.

AI & Machine LearningBiotechDeep Tech

Andrew Phillips(President and Chief Executive Officer)

Co-investorsNew Enterprise Associates (NEA)

Red Ridge Bioredridgebio.com✓ verified

RedRidge Bio discovers and develops biparatopic antibodies (antibodies that bind two sites on a single protein), including biparatopic antibody-drug conjugates, as therapeutics for oncology and autoimmune diseases.

BiotechHealthtech

Bill Sellers(Scientific Founder and Director Cancer Program, Broad Institute)Stephen Yoder(President & CEO)

Co-investorsNew Enterprise Associates (NEA)Sixty Degree Capital

Santa Anasantaana.bio in✓ verified

Santa Ana Bio is a biotech company developing engineered antibody therapeutics that target the immune pathways and cells driving autoimmune and inflammatory diseases.

AI & Machine LearningBiotechHealthtechAlameda, US

Peter Emtage(Founder & CEO)inAlexander Rudensky(Scientific Founder)Richard Flavell(Scientific Founder)Graham Lord(Scientific Founder)Ansuman Satpathy(Scientific Founder)Newman Yeilding(Chief Medical Officer)in

Co-investorsAccess Biotechnology Andreessen Horowitz GV (Google Ventures)RTW Investments L.P.TPG

Tentarixtentarix.com in✓ verified

Tentarix Biotherapeutics develops multifunctional biologics to modernize healthcare standards through precision medicine.

BiotechDeep TechHealthtechMedical Devices

BoardSrini Akkaraju(Director, Founder)Paul Kang(Director, Founder)

Co-investorsSamsara BioCapital

858 Therapeutics, Inc.8five8tx.comJul 2024SEC filingmedium confidence

858 Therapeutics is a clinical-stage biotechnology company developing therapies that target tumor dependencies in DNA damage response pathways for patients with advanced solid tumors.

BiotechHealthtechSan Diego, US

Stafford Jeffrey(Executive Officer, Director)James Veal(Executive Officer)Katherine Bell-McGuinn(Executive Officer)

BoardAli Behbahani(Director)

Board seatClare OzawaMonal MehtaCarlo Rizzuto· per SEC Form D · $50.4M raise · filed Jul 2024

Co-investorsNew Enterprise Associates (NEA)Versant Venture Capital

Aset TherapeuticsMar 2017SEC filingmedium confidence

BiotechStony Brook, US

Elizabeth Buck(Executive Officer)David M Epstein(Executive Officer, Director)

BoardAlexander Mayweg(Director)inGarry E Menzel(Director)

Board seatBrad BolzonAlex Mayweg· per SEC Form D · $12.1M raise · filed Jan 2018

Co-investorsNew Enterprise Associates (NEA)

Chinook Therapeutics U.SFeb 2019SEC filingmedium confidence

Seattle, US

Eric Dobmeier(Executive Officer, Director)Sam Hall(Director)

BoardSrini Akkaraju(Director)inJeremy Caldwell(Director)

Board seatJerel Davis· per SEC Form D · $65M raise · filed Aug 2019

Co-investorsSamsara BioCapital

Concerto HealthcareJul 2015SEC filingmedium confidence

HealthtechIrvine, US

Toby Thomas(Executive Officer)Alec Cunningham(Executive Officer, Director)Cindy Becker(Executive Officer)Samuel R. Willcoxon(Executive Officer, Director)

BoardTimothy Petersen(Director)in

Board seatBarbara Lubash· per SEC Form D · $15.6M raise · filed Jul 2015

Co-investorsArboretum Ventures

Enable Injectionsenableinjections.com in 𝕏Dec 2025SEC filingmedium confidence

Enable Injections develops and manufactures enFuse, a wearable drug delivery device that delivers large volumes of pharmaceutical and biologic therapeutics subcutaneously for patients with chronic diseases.

BiotechHealthtechMedical DevicesCincinnati, US

Mike Hooven(Chairman, President and CEO)inTimothy Flaherty(Executive Officer)Simone Song(Director)Karen Robards(Director)Richard J D'Augustine(Director)Norman R. Weldon(Director)

Board seatBeckie Robertson· per SEC Form D · $30M raise · filed Jan 2026

Co-investorsAngel Physicians Fund CincyTech Lightship Capital Ohio Innovation Fund Magnetar AI Ventures

Firefly Bio, Inc.Dec 2023SEC filingmedium confidence

South San Francisco, US

Board seatJerel DavisAlex Mayweg· per SEC Form D · $72M raise · filed Mar 2024

Co-investorsMPM BioImpact

Graphite Bio, Inc.Mar 2021SEC filingmedium confidence

South San Francisco, US

Board seatJerel DavisCarlo Rizzuto· per SEC Form D · $150.7M raise · filed Mar 2021

Jengu Therapeutics, Inc.Sep 2020SEC filingmedium confidence

BiotechSan Diego, US

ERIC FISCHER(Director)

BoardTHOMAS WOIWODE(Director)inJEREMY CALDWELL(Executive Officer, Director)

Board seatClare Ozawa· per SEC Form D · $50M raise · filed Sep 2020

Jnana Therapeutics Inc.Jan 2024SEC filingmedium confidence

Boston, US

Board seatCarlo Rizzuto· per SEC Form D · $107M raise · filed Jan 2024

Co-investorsPolaris Partners

March Therapeutics, Inc.Sep 2022SEC filingmedium confidence

Cambridge, US

Board seatClare Ozawa· per SEC Form D · $30.3M raise · filed Sep 2022

Mistral TherapeuticsJun 2018SEC filingmedium confidence

BiotechSan Diego, US

Petpiboon Prasit(Director)

BoardJeremy Caldwell(Executive Officer)Bradley Bolzon(Director)

Board seatJerel DavisClare Ozawa· per SEC Form D · $59.3M raise · filed Jun 2018

Nexo Therapeutics, Inc.Mar 2026SEC filingmedium confidence

BiotechLittleton, US

Andrew Phillips(Executive Officer, Director)

BoardAli Behbahani(Director)in

Board seatCarlo Rizzuto· per SEC Form D · $60M raise · filed Mar 2026

Co-investorsNew Enterprise Associates (NEA)

Pandion TherapeuticsJan 2018SEC filingmedium confidence

BiotechCambridge, US

Jo Viney(Executive Officer)Rahul Kakkar(Executive Officer, Director)Anthony Coyle(Executive Officer, Director)Christopher Fuglesang(Director)Donald Frail(Director)Daniel Becker(Director)

Board seatCarlo Rizzuto· per SEC Form D · $80M raise · filed Apr 2020

Co-investorsAccess Biotechnology Polaris Partners

Pep2Tango TherapeuticsNov 2024

BiotechPotomac, US

Cristina Rondinone(Executive Officer, Director)

BoardMickey Kim(Director)Soumitra Ghosh(Director)

Board seatCarlo Rizzuto· per SEC Form D

Presbyopia TherapiesMar 2023SEC filingmedium confidence

BiotechCoronado, US

GERALD HORN(MANAGER)MARK LESTER(MANAGER)JAMES McCOLLUM(MANAGER)

Board seatClare Ozawa· per SEC Form D · $83.5M raise · filed Mar 2023

Turnstone Biologicsturnstonebio.comJan 2019SEC filingmedium confidence

BiotechNew York, US

Michael Burgess(Executive Officer)Jose Manuel Otero(Executive Officer)Robert Gould(Director)Jane Henderson(Executive Officer)Stefan Larson(Director)Patrick Machado(Director)

Board seatBrad BolzonJerel Davis· per SEC Form D · $42.1M raise · filed Jan 2019

Co-investorsBrace Pharma F-Prime Capital FACIT (Fight Against Cancer Innovation Trust)Foothill Ventures Venture Ontario OrbiMed +1 more

Ventus Therapeuticsventustx.com inFeb 2022

Ventus discovers and develops small-molecule medicines using its proprietary ReSOLVE platform, focused on structure-based drug discovery.

AI & Machine LearningBiotechDeep TechHealthtechWaltham, US

Judith Lieberman(Co-Founder, MD, PhD)Daniel Koerwer(Executive Officer)inMichael Crackower(Executive Officer)inZachary McNealy(Executive Officer)

BoardJosh Resnick(Director)

Board seatMarkus WarmuthJerel Davis· per SEC Form D

Co-investorsAndreessen Horowitz GV (Google Ventures)RA Capital SoftBank Vision Fund

AcuFocus, Inc.acufocus.com

BiotechIrvine, US

Alan Waterhouse(President and Chief Operating Officer)Jason Tester(Chief Financial Officer and Secretary)James V. Mazzo(President, Chief Executive Officer and Chairman of the Board)

BoardArjun Arora(Director)Richard L. Lindstrom, M.D.(Director)William J. Link(Director)

Co-investorsEvidity Health Capital Flying L Partners HEALTHCARE ROYALTY PARTNERS SV Life Sciences Versant Venture AIV Holdings

Akeroakerotx.com in 𝕏

Akero develops engineered protein therapies for metabolic diseases, particularly MASH (metabolic dysfunction-associated steatohepatitis) and other conditions with high unmet medical need.

BiotechHealthtechMedical Devices

Co-investorsAtlas Venture Foresite Capital Frazier Life Sciences Scion Life Sciences The Innovation Space venBio Partners

Altergalterg.com in 𝕏

AlterG develops anti-gravity treadmill systems using patented Differential Air Pressure technology to enable rehabilitation and athletic training.

HardwareHealthtechMedical DevicesSports Tech

Anokionanokion.com

Apreaaprea.com

Baseline Therapeuticsbaseline-tx.com

Baseline is a biotech company focused on metabolism, obesity, incretins, and GLP-1-based strategies for substance use disorders, drawing on drug development and addiction medicine expertise.

BiotechDigital HealthHealthtech

Co-investorsVery Serious Ventures

BlueRockbluerocktx.com in

Blue Rock Therapeutics discovers and develops cell therapies to treat disease and improve patient outcomes.

AI & Machine LearningBiotechHealthtechMedical DevicesCambridge, US

Borealis

Chinook Therapeuticschinooktx.com

Co-investorsSamsara BioCapital Scion Life Sciences

CRISPR Therapeutics

Co-investorsKhosla Ventures SR One Capital Management

Enterprise Therapeuticsenterprisetherapeutics.com in 𝕏

Enterprise Therapeutics is a drug discovery company developing therapies for respiratory diseases such as cystic fibrosis, asthma, and COPD.

BiotechHealthtechBrighton, GB

John Ford(Co-founder)Martin Gosling(Founder)in

Co-investorsEpidarex Capital

Epix Therapeuticsin

Medtronic designs and develops medical technology for treating complex diseases.

AI & Machine LearningDigital HealthHealthtechMedical Devices

Co-investors8VC CWRU Technology Ventures Elevate Ventures Menlo Ventures Oak Investment Partners Pfizer Venture Investments+5 more

Fable

Firefly

ForSight VISION5

HealthtechMenlo Park, US

Eugene de Juan, Jr., M.D.(Director)K. Angela Macfarlane(Executive Officer, Director)John F. Maroney(Executive Officer, Director)

BoardRobert C. Bellas, Jr.(Director)Hanson S. Gifford III(Executive Officer, Director)Jim Glasheen(Director)

Co-investorsH.I.G. Capital H.I.G. HealthBridge Partners Lightstone Ventures

Helicorehelicore.comJan 2025

Helicore Bio develops long-acting antibody-peptide conjugate therapies for obesity and cardiometabolic disease, using proprietary GLP-1R agonist and amylin receptor agonist peptide libraries combined with a GIP ligand-binding antibody backbone.

BiotechHealthtech

Co-investorsLongitude Capital OrbiMed Wellington Management

Inari Medicalinarimedical.com in

Inari Medical develops mechanical thrombectomy devices for treating venous thromboembolism conditions, including pulmonary embolism, deep vein thrombosis, in-stent thrombosis, and arteriovenous fistula thrombosis.

HardwareHealthtechMedical DevicesIrvine, US

William H. Hoffman(Executive Officer, Director)inRobert Rosenbluth(Executive Officer, Director)

BoardDonald Milder(Director)Kirk Nielsen(Director)inJonathan Root(Director)inBrian Cox(Director)

Co-investorsGilde Healthcare US Venture Partners Vensana Capital

Inception 4 and 5

Kate Therapeuticskatetherapeutics.com in 𝕏Jun 2023

BiotechSan Diego, US

Kevin Forrest, Ph.D.(Executive Officer, Director)

BoardClare Ozawa, Ph.D.(Director)Beth Seidenberg, M.D.(Director)

Co-investorsWestlake Village BioPartners Osage University Partners

Kolm

Launchpad Therapeutics, Inc.Dec 2022

BiotechCambridge, US

Alexander Mayweg(Executive Officer, Director)Anna Kohlmann(Executive Officer)

BoardAli Behbahani(Director)in

Co-investorsNew Enterprise Associates (NEA)

Lenzlenz-tx.com in 𝕏Mar 2023 · $83.5M

LENZ Therapeutics is a pharmaceutical company developing and commercializing VIZZ™, an FDA-approved aceclidine-based eye drop for treating presbyopia, a vision condition affecting over 128 million people in the US.

BiotechHealthtechMedical DevicesSan Diego, US

James McCollum(Co-founder, Board Member)Eef SchimmelpenninkinEvert Schimmelpennink(President and CEO)

Co-investorsAlpha Wave Global RA Capital Raptor Group RTW Investments L.P.Sectoral Asset Management

Matterhorn Biosciences

MetaventionDec 2017

Eden Prairie, US

Bobak Azamian(Executive Officer, Director)Tony Vrba(Executive Officer)Kevin Hykes(Executive Officer, Director)Kirk Nielsen(Director)

Co-investorsSanderling Ventures New Enterprise Associates (NEA)

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

Exits · 5

IPOs and acquisitions across the tracked portfolio

Monte Rosa TherapeuticsNASDAQ: GLUECentury Therapeutics, Inc.NASDAQ: IPSCBlack Diamond TherapeuticsNASDAQ: BDTXPassage BioNASDAQ: PASGVividion Therapeuticsacq. by Bayer

Portfolio news

latest coverage across their companies

Passage Bio posts Q2 loss and plans Remix merger | PASG Quarterly Report (10-Q)

Passage Bio · stocktitan.net · Aug 10, 2026

What Monte Rosa Therapeutics (GLUE)'s Swing From Profit To Deeper Losses Means For Shareholders - Simply Wall St News

Monte Rosa Therapeutics · simplywall.st · Aug 9, 2026

Lycia Therapeutics has filed a notice of an exempt offering of securities to raise $75 Million in New Funding. - intelligence360

Lycia Therapeutics · intelligence360.news · Jul 22, 2026

Selling Cyber: Anthropic's Fable 5 Raises Security Tradeoffs

Fable · bankinfosecurity.com · Jul 8, 2026

The 29-year old investor who went from selling fake IDs to backing Poppi raises a $75 million fund | Fortune

Second Sight · fortune.com · Feb 23, 2026

Biotech Funding 2025 Tracker: Follow the Latest Raises, Rounds and R&D Momentum - Xtalks

Dualitas Therapeutics · xtalks.com · Jan 8, 2026

Bright Peak Therapeutics secures investment of 90 million US dollars | S-GE

Bright Peak Therapeutics · s-ge.com · Nov 4, 2025

Switzerland: Granite Bio emerges from stealth with US$100m in funding - Investors in Healthcare

Granite Bio · investorsinhealthcare.com · Apr 25, 2025

Fund performance · per public LP disclosures · 3

as of Sep 2025

Fund	Vintage	Committed	Net IRR	TVPI	DPI
Versant Venture VII, L.P.LPs: San Diego City Employees' Retirement System	2018	—	9.6%	1.50x	0.37x
Versant Venture VI, L.P.LPs: San Diego City Employees' Retirement System	2017	—	16.0%	1.81x	1.16x
Versant Venture Capital II, L.PLPs: The Regents of the University of California, Richard King Mellon Foundation	2001	—	4.2%	1.33x	1.33x

Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).

Public market activity · per SEC filings

what is this? ⓘ

2 insider ownership filings (Forms 3/4/5)

Files 13F institutional holdings reports · latest Aug 2026

From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.

Frequently asked questions

How many investments has Versant Ventures made?: Versant Ventures has 27 tracked investments.
What stage does Versant Ventures invest at?: Versant Ventures invests at the Seed, Series A, Series B, Series C, Late Stage stages.
What is Versant Ventures's typical check size?: Versant Ventures typically writes checks of $250K – $5M.
What sectors does Versant Ventures focus on?: Versant Ventures focuses on Biotech, Healthtech.
Where is Versant Ventures located?: Versant Ventures is headquartered in San Francisco, US.
Does Versant Ventures lead rounds?: Versant Ventures typically participates in rounds rather than leading them.
Who does Versant Ventures co-invest with?: Versant Ventures most often shares deals with RA Capital, Scion Life Sciences, Foresite Capital, among 33 tracked co-investors.

Media · Podcasts & interviews

featuring the team

Carlo Rizzuto, Partner at Versant Ventures, on NewYorkBIO's #VirtualBreakfastSeries

NewYorkBIO Video Channel · Carlo Rizzuto

Carlo Rizzuto (Versant Ventures) | Videos & Movies on Vimeo

Columbia Tech Ventures · Carlo Rizzuto · vimeo.com

Images

Co-investors · 44

New Enterprise Associates (NEA)

New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.

Both backed · 9

Monte Rosa Therapeutics 858 Therapeutics, Inc.Aset Therapeutics Launchpad Therapeutics, Inc.Metavention Nexo Nexo Therapeutics, Inc.Oyster Point Pharma, Inc.Red Ridge Bio

$200K – $40M

GV (Google Ventures)

GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.

Both backed · 6

Monte Rosa Therapeutics Gate Bio Santa Ana Santa Ana Bio Ventus Ventus Therapeutics

$250K – $50M

RA Capital

RA Capital is a multi-stage investment firm focused on healthcare, life sciences, and planetary health, investing across public and private markets and creating new companies through its Raven incubation platform.

Both backed · 6

Black Diamond TherapeuticsBright Peak Therapeutics Lenz T-Knife Ventus Ventus Therapeutics

Andreessen Horowitz

Andreessen Horowitz (a16z) is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz, known for pioneering the platform model with a large team of operators supporting founders across stages.

Both backed · 5

Gate Bio Santa Ana Santa Ana Bio Ventus Ventus Therapeutics

$500K – $50M

OrbiMed

OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.

Both backed · 5

Passage Bio Helicore Iecure Lycia Therapeutics Turnstone Biologics

$1M – $75M

Samsara BioCapital

Samsara BioCapital is an investment firm backing the development of transformative therapeutics for patients, bringing together scientists, physicians, drug developers, and business leaders to support next-generation therapeutic breakthroughs.

Both backed · 4

Chinook Therapeutics U.S Rayze Bio TentarixChinook Therapeutics

MPM BioImpact

MPM BioImpact combines 30+ years of biotech venture capital expertise with impact investing and public market experience, managing early-stage venture funds, private/public impact funds, and a public equities fund focused on transforming patient outcomes.

Both backed · 3

Fable NeoVistaFirefly Bio, Inc.

$1M – $15M

Polaris Partners

Polaris Partners is a venture capital firm that partners with biotech and healthcare entrepreneurs to build transformational companies.

Both backed · 2

Pandion TherapeuticsJnana Therapeutics Inc.

$500K – $5M

ARCH Venture Partners

ARCH Venture Partners is a venture capital firm that invests in and helps build transformational companies, with a strong focus on the life sciences and biotechnology sector.

Both backed · 2

Gate Bio Vividion Therapeutics

$50K – $250M

Forbion

Forbion is a global venture capital firm focused on advancing biotech innovations and sustainable solutions aimed at improving human and planetary health.

Both backed · 2

Gate Bio Granite Bio

venBio Partners

venBio is a life sciences venture capital firm that partners with industry leaders to develop novel therapeutics and technologies addressing unmet medical needs.

Both backed · 2

Akero Rayze Bio

Vivo Capital

Vivo Capital is a global healthcare-focused investment firm operating a multi-strategy platform spanning venture capital, private equity, and public equity. It aims to expand healthcare access and drive innovation through its 'Ecosystem Strategy.'

Both backed · 2

Passage Bio Rayze Bio

$10M – $50M

▶32 more co-investors

Avoro Capital Advisors Casdin Capital Canaan Partners F-Prime Capital Venrock SR One Capital Management 5AM Ventures Sanofi Ventures Aisling Capital Frazier Healthcare Partners Andera Partners Nextech Invest New Leaf Venture Partners HBM Partners Unknown Ventures Kleiner Perkins General Atlantic Wildcat Venture Partners Earlybird Venture Capital Highland Capital Partners EQT Life Sciences OUP (Osage University Partners)The Column Group Domain Associates Abingworth Access Industries Ysios Capital Volition Capital Amplitude Venture Capital KohFounders Elo Health Buff Gold Ventures

Firms observed investing alongside Versant Ventures, from public investor directories. Shared companies are the overlap with Versant Ventures's recorded portfolio.

Similar investors

Legendary Ventures, Llc.

Legendary Ventures is a venture capital firm focused on consumer, retail, and technology (CRT) companies, combining the expertise of venture capitalists and retail executives to support portfolio companies and identify acquisition partners.

Speedinvest

Speedinvest operates a Portfolio Success program that connects its 400+ portfolio startups with customers, follow-on investors, industry experts, talent, discounted tools, and fellow founders across Europe, the Middle East, Africa, and beyond.

$5M – $30M

Korea Investment Partners

Korea Investment Partners is a South Korea-based venture capital firm that invests across multiple stages from early-stage startups through growth and buyout transactions, including venture debt and mezzanine financing. The firm operates across venture capital, middle market, and growth equity investment categories.

$973K – $50M

Celesta Capital

Celesta Capital is a venture capital firm that invests in deep tech companies at the forefront of science and engineering.

$5M – $20M

New Science Ventures

New Science Ventures (NSV) is a venture capital firm based in Connecticut and London that backs companies applying novel scientific approaches in the life sciences and information technology sectors.

$2M – $8M